Determining the exact activation mechanisms of NLRP1, NLRP3 and NLRC4 (as the main components of the inflammasome) and the regulator molecules of the inflammasome pathway, the effect of the inflammasomes on different cell types and host antitumor immunity and immunotherapy during tumor growth and progression could be accomplished by evaluating the dysregulation or mutation of inflammasome components, using animal models or cancer cell lines. Here, NLRP1 is linked to neoplasm.